Related to Abraxis Reports Phase III Success with Abraxane in First-Line NSCLC

• Abbott to Develop Molecular Companion Diagnostic for Pfizer’s NSCLC Drug Candidate
  
• Lilly Allies with Almac to Develop a Companion Diagnostic for NSCLC Drug
  
• ProMetic and Abraxis Team Up to Develop New Applications of Prion-Capture Platform
  
• Scientists Pinpoint 93-Gene Signature that Predicts Non-Small-Cell Lung Cancer Prognosis
  
• Investigators Link Age- and Gender-Specific Gene Profiles in NSCLC to Recurrence-Free Survival
  
• FDA Grants New Approval for Rituxan in CD20-Positive CLL
  
• FDA Okays Tarceva as Maintenance Therapy of NSCLC after Chemotherapy
  
• NicOx’ Value Plunges 43% as FDA Advisers Recommend against Approving Osteoarthritis Therapy
  
• OSI Accepts Astellas' Increased $4B Cash Takeover Offer
  
• T2cure’s Mid-Stage Somatic Stem Cell Product Receives EMEA Quality Certification
  
• Genzyme to Give Up $175M in Profits under Consent Decree to Rectify Issues at Production Plant
  
• Clovis Signs On to Advance Avila’s Preclinical EGFR Mutant-Selective Inhibitor Program
  
• Pozen Gets $20M from AstraZeneca after U.S. Approval of Vimovo
  
• FDA Approves Genzyme Product for Late-Onset Pompe Disease
  
• Celera Gets CE Mark for KIF6 Genetic Test for Coronary Heart Disease Risk
  
• FDA Lifts Clinical Hold on Proellex to Allow Escalating Low-Dose Safety and Efficacy Trial
  
• Santhera Confirms Plans to File Catena for Treating LHON Eye Disease
  
• FDA Green-Lights Novartis’ Tasigna as First-Line Therapy for Newly Diagnosed Ph+ CML
  
• FDA Sanctions Abbott’s Test that Detects HIV Antigen and Antibodies
  
• Pfizer to Withdraw AML Drug Following Disappointing Postapproval Trial Results